206 related articles for article (PubMed ID: 24919593)
1. Aberrant PTPRO methylation in tumor tissues as a potential biomarker that predicts clinical outcomes in breast cancer patients.
Li SY; Li R; Chen YL; Xiong LK; Wang HL; Rong L; Luo RC
BMC Genet; 2014 Jun; 15():67. PubMed ID: 24919593
[TBL] [Abstract][Full Text] [Related]
2. PTPRO promoter methylation is predictive of poorer outcome for HER2-positive breast cancer: indication for personalized therapy.
Huang YT; Li FF; Ke C; Li Z; Li ZT; Zou XF; Zheng XX; Chen YP; Zhang H
J Transl Med; 2013 Oct; 11():245. PubMed ID: 24090193
[TBL] [Abstract][Full Text] [Related]
3. Aberrant methylation of the PTPRO gene in peripheral blood as a potential biomarker in esophageal squamous cell carcinoma patients.
You YJ; Chen YP; Zheng XX; Meltzer SJ; Zhang H
Cancer Lett; 2012 Feb; 315(2):138-44. PubMed ID: 22099875
[TBL] [Abstract][Full Text] [Related]
4. Estrogen-mediated suppression of the gene encoding protein tyrosine phosphatase PTPRO in human breast cancer: mechanism and role in tamoxifen sensitivity.
Ramaswamy B; Majumder S; Roy S; Ghoshal K; Kutay H; Datta J; Younes M; Shapiro CL; Motiwala T; Jacob ST
Mol Endocrinol; 2009 Feb; 23(2):176-87. PubMed ID: 19095770
[TBL] [Abstract][Full Text] [Related]
5. Epigenetically silenced PTPRO functions as a prognostic marker and tumor suppressor in human lung squamous cell carcinoma.
Ming F; Sun Q
Mol Med Rep; 2017 Jul; 16(1):746-754. PubMed ID: 28586036
[TBL] [Abstract][Full Text] [Related]
6. Expression profiling during mammary epithelial cell three-dimensional morphogenesis identifies PTPRO as a novel regulator of morphogenesis and ErbB2-mediated transformation.
Yu M; Lin G; Arshadi N; Kalatskaya I; Xue B; Haider S; Nguyen F; Boutros PC; Elson A; Muthuswamy LB; Tonks NK; Muthuswamy SK
Mol Cell Biol; 2012 Oct; 32(19):3913-24. PubMed ID: 22851698
[TBL] [Abstract][Full Text] [Related]
7. Suppression of the protein tyrosine phosphatase receptor type O gene (PTPRO) by methylation in hepatocellular carcinomas.
Motiwala T; Ghoshal K; Das A; Majumder S; Weichenhan D; Wu YZ; Holman K; James SJ; Jacob ST; Plass C
Oncogene; 2003 Sep; 22(41):6319-31. PubMed ID: 14508512
[TBL] [Abstract][Full Text] [Related]
8. Methylation and silencing of protein tyrosine phosphatase receptor type O in chronic lymphocytic leukemia.
Motiwala T; Majumder S; Kutay H; Smith DS; Neuberg DS; Lucas DM; Byrd JC; Grever M; Jacob ST
Clin Cancer Res; 2007 Jun; 13(11):3174-81. PubMed ID: 17545520
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of FBXW7/hCDC4-β expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer.
Akhoondi S; Lindström L; Widschwendter M; Corcoran M; Bergh J; Spruck C; Grandér D; Sangfelt O
Breast Cancer Res; 2010; 12(6):R105. PubMed ID: 21122106
[TBL] [Abstract][Full Text] [Related]
10. Sox17 promoter methylation in plasma DNA is associated with poor survival and can be used as a prognostic factor in breast cancer.
Fu D; Ren C; Tan H; Wei J; Zhu Y; He C; Shao W; Zhang J
Medicine (Baltimore); 2015 Mar; 94(11):e637. PubMed ID: 25789956
[TBL] [Abstract][Full Text] [Related]
11. Intermediate filament dynamics and breast cancer: aberrant promoter methylation of the Synemin gene is associated with early tumor relapse.
Noetzel E; Rose M; Sevinc E; Hilgers RD; Hartmann A; Naami A; Knüchel R; Dahl E
Oncogene; 2010 Aug; 29(34):4814-25. PubMed ID: 20543860
[TBL] [Abstract][Full Text] [Related]
12. Hypermethylation of CDKN2A exon 2 in tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients.
Spitzwieser M; Entfellner E; Werner B; Pulverer W; Pfeiler G; Hacker S; Cichna-Markl M
BMC Cancer; 2017 Apr; 17(1):260. PubMed ID: 28403857
[TBL] [Abstract][Full Text] [Related]
13. Protein expression and methylation of MGMT, a DNA repair gene and their correlation with clinicopathological parameters in invasive ductal carcinoma of the breast.
Asiaf A; Ahmad ST; Malik AA; Aziz SA; Rasool Z; Masood A; Zargar MA
Tumour Biol; 2015 Aug; 36(8):6485-96. PubMed ID: 25820821
[TBL] [Abstract][Full Text] [Related]
14. DNA methylation and breast cancer: A way forward (Review).
Vietri MT; D'Elia G; Benincasa G; Ferraro G; Caliendo G; Nicoletti GF; Napoli C
Int J Oncol; 2021 Nov; 59(5):. PubMed ID: 34726251
[TBL] [Abstract][Full Text] [Related]
15. Prognostic relevance of Wnt-inhibitory factor-1 (WIF1) and Dickkopf-3 (DKK3) promoter methylation in human breast cancer.
Veeck J; Wild PJ; Fuchs T; Schüffler PJ; Hartmann A; Knüchel R; Dahl E
BMC Cancer; 2009 Jul; 9():217. PubMed ID: 19570204
[TBL] [Abstract][Full Text] [Related]
16. Single CpG hypermethylation, allele methylation errors, and decreased expression of multiple tumor suppressor genes in normal body cells of mutation-negative early-onset and high-risk breast cancer patients.
Böck J; Appenzeller S; Haertle L; Schneider T; Gehrig A; Schröder J; Rost S; Wolf B; Bartram CR; Sutter C; Haaf T
Int J Cancer; 2018 Sep; 143(6):1416-1425. PubMed ID: 29659014
[TBL] [Abstract][Full Text] [Related]
17. Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.
Veeck J; Bektas N; Hartmann A; Kristiansen G; Heindrichs U; Knüchel R; Dahl E
Breast Cancer Res; 2008; 10(5):R82. PubMed ID: 18826564
[TBL] [Abstract][Full Text] [Related]
18. Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors.
Sunami E; Shinozaki M; Sim MS; Nguyen SL; Vu AT; Giuliano AE; Hoon DS
Breast Cancer Res; 2008; 10(3):R46. PubMed ID: 18485221
[TBL] [Abstract][Full Text] [Related]
19. Dysregulation of the epigenome in triple-negative breast cancers: basal-like and claudin-low breast cancers express aberrant DNA hypermethylation.
Roll JD; Rivenbark AG; Sandhu R; Parker JS; Jones WD; Carey LA; Livasy CA; Coleman WB
Exp Mol Pathol; 2013 Dec; 95(3):276-87. PubMed ID: 24045095
[TBL] [Abstract][Full Text] [Related]
20. Detection of 14-3-3 sigma (σ) promoter methylation as a noninvasive biomarker using blood samples for breast cancer diagnosis.
Ye M; Huang T; Ying Y; Li J; Yang P; Ni C; Zhou C; Chen S
Oncotarget; 2017 Feb; 8(6):9230-9242. PubMed ID: 27999208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
